Clinical Observation of Intravitreal Injection of Ranibizumab Combined with Argon Laser Therapy in the Treatment of Ischemic Neovascular Glaucoma
10.6039/j.issn.1001-0408.2018.10.21
- VernacularTitle:玻璃体内注射雷珠单抗联合氩激光治疗缺血性新生血管性青光眼的临床观察
- Author:
Zhihui LIN
1
;
Zhiliang WANG
;
Wei WANG
;
Chunfa NIE
;
Rongrong ZHANG
Author Information
1. 河北省眼科医院/河北省眼科学重点实验室/河北省眼科研究所糖尿病眼病科
- Keywords:
Ranibizumab;
Argon laser therapy;
Ischemic neovascular glaucoma;
Intraocular pressure;
Visual acuity
- From:
China Pharmacy
2018;29(10):1380-1383
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy and safety of intravitreal injection of ranibizumab combined with argon laser therapy in the treatment of ischemic neovascular glaucoma. METHODS:A total of 166 patients with neovascular glaucoma selected from our hospital during Mar. 2014-Mar. 2016 were divided into control group and observation group according to random number table,with 88 cases in each group(there were 117 and 125 eyes respectively). Both groups received argon laser photocoagulation therapy twice a week for 1 month. Observation group was additionally given intravitreal injection of Ranibizumab injection(0.5 mg)once a week,for 1 month. Clinical efficacies of 2 groups were observed,and the intraocular pressure and visual acuity of 2 groups were observed before treatment,1 week and 1 month after treatment. The occurrence of ADR was recorded. RESULTS:After 1 month of treatment,total response rate was 95.20％ in observation group,which was significantly higher than 76.92％ in control group,with statistical significance (P<0.05). After 1 week of treatment,intraocular pressures of observation group were lower than before treatment and control group at the same time,while visual acuity was better than before treatment and control group at the same time,with statistical significance (P<0.05). After 1 month of treatment,intraocular pressures of 2 groups were decreased significantly and visual acuity was significantly improved;intraocular pressure was decreased and visual acuity was improved more significantly in observation group than control group,with statistical significance(P<0.05 or P<0.01). The incidences of ADR of 2 groups were 3.41％ and 2.27％,without statistical significance (P>0.05). CONCLUSIONS:The ischemic intravitreal injection of ranibizumab combined with argon laser therapy is better than argon laser therapy alone in the treatment of ischemic neovascular glaucoma,and can significantly reduce intraocular pressure and improve visual acuity with good safety.
